Inclisiran: extension study started

The Medicines Co. began the open-label ORION-3 extension study to compare subcutaneous inclisiran vs. Repatha evolocumab in patients who have completed the double-blind, placebo-controlled, international Phase II ORION-1 trial. Patients who received inclisiran in ORION-1 will continue to receive inclisiran, and those who received placebo will receive Repatha as comparator for 1 year, after which they will switch to inclisiran for the remainder of the study. The company said the study will continue for 4 years or until inclisiran receives regulatory approval, whichever occurs first...